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Background
In clinical trials, treatment with a combination of the nucleotide polymerase inhibi-
tor sofosbuvir and the antiviral drug ribavirin was associated with high response 
rates among patients with hepatitis C virus (HCV) genotype 2 infection, with lower 
response rates among patients with HCV genotype 3 infection.
Methods
We conducted a study involving patients with HCV genotype 2 or 3 infection, some 
of whom had undergone previous treatment with an interferon-based regimen. We 
randomly assigned 91 patients with HCV genotype 2 infection and 328 with HCV 
genotype 3 infection, in a 4:1 ratio, to receive sofosbuvir–ribavirin or placebo for 
12 weeks. On the basis of emerging data from phase 3 trials indicating that patients 
with HCV genotype 3 infection had higher response rates when they were treated 
for 16 weeks, as compared with 12 weeks, the study was unblinded, treatment for 
all patients with genotype 3 infection was extended to 24 weeks, the placebo group 
was terminated, and the goals of the study were redefined to be descriptive and not 
include hypothesis testing. The primary end point was a sustained virologic response 
at 12 weeks after the end of therapy.
Results
Of the 419 patients who were enrolled and treated, 21% had cirrhosis and 58% had 
received previous interferon-based treatment. The criterion for a sustained virologic 
response was met in 68 of 73 patients (93%; 95% confidence interval [CI], 85 to 98) 
with HCV genotype 2 infection who were treated for 12 weeks and in 213 of 250 pa-
tients (85%; 95% CI, 80 to 89) with HCV genotype 3 infection who were treated for 
24 weeks. Among patients with HCV genotype 3 infection, response rates were 91% 
and 68% among those without and those with cirrhosis, respectively. The most com-
mon adverse events were headache, fatigue, and pruritus.
Conclusions
Therapy with sofosbuvir–ribavirin for 12 weeks in patients with HCV genotype 2 
infection and for 24 weeks in patients with HCV genotype 3 infection resulted in 
high rates of sustained virologic response. (Funded by Gilead Sciences; VALENCE 
ClinicalTrials.gov number, NCT01682720.)
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Of the six main genotypes of the hepatitis C virus (HCV), genotypes 2 and 3 account for approximately 30% of chronic 
infections worldwide.1 Although these two geno-
types have historically been grouped together in 
treatment guidelines and clinical trials,2,3 accu-
mulating evidence suggests that there are impor-
tant clinical differences between them.1,4,5 HCV 
genotype 3 infection is associated with a higher 
incidence of hepatic steatosis, more rapid pro-
gression of fibrosis, and possibly a greater risk of 
hepatocellular carcinoma than is HCV genotype 2 
infection.6 Moreover, patients with HCV genotype 3 
infection are less responsive to peginterferon-
based treatment than are patients with HCV geno-
type 2 infection.7-9 Until recently, peginterferon 
plus ribavirin administered for 24 weeks was the 
standard treatment for patients with either geno-
type 2 or genotype 3 infection.2,3 However, the 
ongoing discovery and development of agents 
that directly target various stages of HCV replica-
tion are likely to provide HCV-infected patients 
with effective interferon-free therapy.10-12
Sofosbuvir is an oral nucleotide analogue in-
hibitor of the HCV NS5B polymerase that is ef-
fective against HCV genotypes 2 and 3 when it is 
administered in combination with ribavirin.13,14 
In phase 3 trials involving patients with HCV 
genotype 2 or 3 infection, therapy with sofosbuvir–
ribavirin for 12 weeks resulted in rates of sustained 
virologic response of 67% among patients who had 
not undergone previous interferon-based therapy 
and 78% among patients for whom peg interferon 
therapy was not possible because of contraindica-
tions or in whom unacceptable side effects devel-
oped. Among patients who had undergone previ-
ous therapy, rates of sustained virologic response 
were 50% among those who received 12 weeks of 
sofosbuvir–ribavirin and 73% among those who 
received 16 weeks of the drug combination.14 In all 
the phase 3 studies of sofosbuvir–ribavirin, higher 
rates of sustained virologic response were observed 
among patients with genotype 2 infection than 
among those with genotype 3 infection.
We conducted a study of sofosbuvir and riba-
virin that included patients who had not received 
previous treatment and those who had undergone 
previous treatment. The purpose of our study was 
to assess the efficacy of 24 weeks of sofosbuvir–
ribavirin therapy in patients with HCV genotype 3 
infection and to confirm previous findings with 
respect to 12 weeks of therapy in patients with 
HCV genotype 2 infection.
Me thods
Patients
We enrolled patients from September 2012 through 
January 2013 at 77 sites in Europe. Eligible pa-
tients were 18 years of age or older and had 
chronic infection with HCV genotype 2 or 3, with 
serum HCV RNA levels of 10,000 IU per milliliter 
or higher. Patients could participate in the study 
regardless of whether they had received previous 
therapy for HCV infection with an interferon-
based regimen. Some of the study patients either 
had not had a sustained virologic response after 
at least 12 weeks of previous treatment with an 
interferon-based regimen or had discontinued 
interferon treatment after no more than 12 weeks 
of treatment because of severe adverse reactions, 
psychiatric disease requiring hospitalization, 
major disability, or other recognized side effects 
of interferon. According to prespecified criteria, 
approximately 20% of patients who were enrolled 
could have cirrhosis. All patients provided written 
informed consent. Full eligibility criteria, includ-
ing details of the assessment for cirrhosis and rea-
sons for ineligibility for interferon treatment are 
provided in the Supplementary Appendix, available 
with the full text of this article at NEJM.org.
Study Design
The study was initially designed as a multicenter 
phase 3 trial. Patients were randomly assigned, in 
a 4:1 ratio, to receive either sofosbuvir–ribavirin 
or matching placebo. Randomization was strati-
fied according to status with respect to previous 
therapy (no previous therapy or previous therapy) 
and the presence or absence of cirrhosis at the 
time of screening. Sofosbuvir (Gilead Sciences) 
was administered orally at a dose of 400 mg once 
daily. Ribavirin (Ribasphere, Kadmon) was admin-
istered orally twice daily, with doses determined 
according to body weight (1000 mg daily in pa-
tients with a body weight of <75 kg and 1200 mg 
daily in patients with a body weight of ≥75 kg).
The study design originally called for all  patients 
to receive 12 weeks of treatment with sofosbuvir–
ribavirin or matching placebo. However, after the 
initiation of the study, newly available results from 
the FUSION phase 3 study of sofosbuvir strongly 
suggested that patients with HCV genotype 3 infec-
tion could benefit from extending treatment be-
yond 12 weeks.14 The study protocol was accord-
ingly amended so that the study-group assignments 
were unblinded, the placebo group was terminated, 
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patients with HCV genotype 2 infection were 
treated as originally planned for 12 weeks, and 
the treatment of patients with HCV genotype 3 
infection was extended to 24 weeks. Patients 
with HCV genotype 3 infection who had already 
completed 12 weeks of treatment before the 
amendment was approved were not given addi-
tional treatment. Patients in the discontinued 
placebo group were offered open-label treatment 
with sofosbuvir–ribavirin in another clinical 
trial (ClinicalTrials.gov number, NCT01625338), 
with a duration based on the HCV genotype.
The study was redefined as a descriptive study 
to characterize sustained response rates in patients 
with HCV genotype 2 infection who were treated 
for 12 weeks and in patients with HCV genotype 3 
infection who were treated for 24 weeks, with no 
plans for hypothesis testing. Details regarding 
the assessments that were used in the study are 
provided in the Supplementary Appendix.
Primary End Point
The primary efficacy end point was a sustained 
virologic response at 12 weeks after the end of 
treatment. This response was defined as a level of 
HCV RNA below the lower limit of quantification 
(25 IU per milliliter).
Study Oversight
This study was approved by the institutional review 
board or independent ethics committee at each par-
ticipating site and was conducted in compliance 
with the provisions of the Declaration of Helsinki, 
Good Clinical Practice guidelines, and local regula-
tory requirements. The study was designed and con-
ducted according to protocol by the sponsor (Gile-
ad) in collaboration with the principal investigators. 
The sponsor collected the data, monitored the con-
duct of the study, and performed the statistical 
analyses. An independent data and safety monitor-
ing committee reviewed the progress of the study. 
The investigators, participating institutions, and 
sponsor agreed to maintain the confidentiality of 
the data. All the authors vouch for the completeness 
and accuracy of the data and data analyses and for 
the fidelity of this report to the study protocol, 
which is available at NEJM.org. The manuscript was 
prepared by Gilead Sciences and the first author 
with input from all the authors.
Statistical Analysis
In the original analysis plan, we determined that 
a sample size of 320 patients in the sofosbuvir–
ribavirin group and 80 patients in the placebo 
group would provide a power of 99% to detect a 
difference between the two groups, assuming rates 
of sustained virologic response of 45% and 5%, 
respectively, on the basis of a two-sided continuity-
corrected chi-square test at a significance level 
of 0.05. As a result of the study amendment and 
unblinding of the study-group assignments, all the 
patients in the placebo group were discontinued 
from the study, and the primary objective was 
changed to provide descriptive estimates of effi-
cacy within each active-treatment group, with no 
comparison with placebo and no hypothesis test-
ing. We calculated the proportion of patients who 
had a sustained virologic response along with 
exact two-sided 95% confidence intervals con-
structed with the use of the Clopper–Pearson 
method for each active-treatment group and for 
subgroups. In an exploratory analysis, we per-
formed a multivariate logistic-regression analy-
sis involving baseline demographic and clinical 
characteristics, using a stepwise procedure to 
identify independent predictors of a sustained 
virologic response.
R esult s
Patients
A total of 475 patients were screened for enroll-
ment (Fig. S1 in the Supplementary Appendix). 
Of these patients, 421 underwent randomization 
and 419 began treatment.
The demographic and clinical characteristics of 
the patients at baseline are shown in Table 1. Over-
all, 40% were women, 21% had cirrhosis, and 58% 
had been previously treated for HCV infection, of 
whom 30% had had no response. The characteris-
tics of the patients were generally balanced among 
the study groups, with expected differences be-
tween patients with HCV genotype 2 infection and 
those with HCV genotype 3 infection.
Efficacy
Patients receiving sofosbuvir–ribavirin had sub-
stantial reductions in circulating HCV RNA lev-
els during the first weeks of treatment (Table 2). 
By week 4 of treatment, 99% of the patients had 
an HCV RNA level of less than 25 IU per milliliter. 
No patients in the placebo group had an HCV 
RNA level of less than 25 IU per milliliter at any 
time point.
Among patients with HCV genotype 2 infection 
who received 12 weeks of sofosbuvir–ribavirin, 
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68 of 73 (93%; 95% confidence interval [CI], 85 to 
98) had a sustained virologic response 12 weeks 
after the cessation of treatment (Table 2). All 
68 patients also had a sustained virologic re-
sponse 24 weeks after treatment. Among patients 
with HCV genotype 3 who received 24 weeks of 
sofosbuvir–ribavirin, 213 of 250 patients (85%; 
95% CI, 80 to 89) had a sustained virologic re-
sponse 12 weeks after the cessation of treat-
ment. Of these 213 patients, 206 had a sustained 
virologic response 24 weeks after treatment, 2 had 
a virologic relapse, 4 were lost to follow-up after 
post-treatment week 12, and 1 had an invalid 
HCV RNA result because the visit occurred out-
side the window of 24 weeks after treatment.
Exploratory analyses revealed that among pa-
tients with HCV genotype 2 infection, the rates 
of response were consistently high across sub-
groups (Fig. 1, and Table S1 in the Supplemen-
tary Appendix). Rates of sustained virologic re-
sponse among patients with HCV genotype 3 
infection varied according to treatment history 
and status with respect to cirrhosis. Among 
patients who had not received previous treat-
ment, the rates of sustained virologic response 
were 92% among those with cirrhosis and 95% 
among those without cirrhosis (Fig. S2 in the 
Supplementary Appendix). However, among 
previously treated patients with HCV genotype 3 
infection, the rates of sustained virologic re-
sponse were lower: 62% among those with cir-
rhosis and 87% among those without cirrhosis. 
Among patients with HCV genotype 3 infection, 
overall response rates were 68% among those 
Table 1. Demographic and Clinical Characteristics of the Patients at Baseline.*
Characteristic Genotype 2 or 3 Genotype 2 Genotype 3
Placebo 
for 12 Wk
(N = 85)†
Sofosbuvir 
plus Ribavirin 
for 12 Wk 
(N = 73)
Sofosbuvir 
plus Ribavirin  
for 12 Wk 
(N = 11)
Sofosbuvir 
plus Ribavirin 
for 24 Wk 
(N = 250)
Mean age (range) — yr‡ 49 (19–72) 58 (28–74) 46 (30–59) 48 (19–69)
Mean body-mass index (range)§ 26 (18–40) 26 (20–35) 28 (20–44) 25 (17–41)
Male sex — no. (%) 49 (58) 40 (55) 6 (55) 155 (62)
Race — no. (%)¶
White 81 (95) 65 (89) 11 (100) 236 (94)
Black 1 (1) 5 (7) 0 0
Asian 3 (4) 1 (1) 0 9 (4)
Not reported 0 2 (3) 0 5 (2)
Ethnic group — no. (%)¶
Hispanic or Latino 10 (12) 6 (8) 1 (9) 36 (14)
Not Hispanic or Latino 71 (84) 65 (89) 10 (91) 203 (81)
Not reported 4 (5) 2 (3) 0 11 (4)
HCV genotype‡
2 18 (21) 73 (100) 0 0
3 67 (79) 0 11 (100) 250 (100)
HCV RNA — log10 IU/ml 6.5±0.7 6.5±0.7 6.2±0.8 6.3±0.7
HCV RNA ≥6 log10 IU/ml — no. (%) 64 (75) 57 (78) 7 (64) 178 (71)
IL28B genotype — no. (%)
CC 22 (26) 24 (33) 4 (36) 86 (34)
CT 49 (58) 41 (56) 4 (36) 131 (52)
TT 14 (16) 8 (11) 3 (27) 33 (13)
Cirrhosis — no. (%) 17 (20) 11 (15) 2 (18) 60 (24)
Baseline alanine aminotransferase >1.5× ULN  
— no. (%)‡
53 (62) 34 (47) 7 (64) 186 (74)
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with cirrhosis and 91% among those without 
cirrhosis. In an exploratory multivariate regres-
sion analysis of patients with genotype 3 infec-
tion, four factors were independently associated 
with a sustained virologic response: a baseline 
HCV RNA level of less than 6 log10 IU per mil-
liliter (odds ratio, 4.23; 95% CI, 1.21 to 14.81; 
P = 0.02), female sex (odds ratio, 3.18; 95% CI, 
1.22 to 8.31; P = 0.02), absence of cirrhosis (odds 
ratio, 3.46; 95% CI, 1.60 to 7.48; P = 0.002), and 
an age of less than 50 years (odds ratio, 2.82; 
95% CI, 1.21 to 6.57; P = 0.02) (Table S5 in the 
Supplementary Appendix).
Of the 334 patients receiving sofosbuvir–
ribavirin, 1 had a virologic breakthrough during 
treatment. According to a subsequent pharmaco-
kinetic analysis, this patient had undetectable 
drug levels during weeks 12 through 24 of treat-
ment, suggesting nonadherence.
Viral Resistance Testing
The S282T variant is the only HCV mutation that 
has been found to reduce susceptibility to sofos-
buvir in vitro. S282T variants were not detected at 
baseline in any patient, nor were they detected by 
means of deep sequencing at the time of viro-
logic failure in the patients who did not have a 
sustained virologic response. Among the 41 pa-
tients with HCV genotype 3 infection who had 
virologic failure, the mutations that have been 
associated with sofosbuvir treatment — V321A 
and L159F — were detected in 2 and 6 patients, 
respectively. The V321A mutation was not ob-
served at baseline in any patient, and L159F was 
not assessed at baseline in this study, since only 
short-fragment sequencing from NS5B positions 
227–338 was performed. During in vitro testing, 
neither the V321A mutation nor the L159F muta-
tion conferred resistance to sofosbuvir. The clin-
Table 1. (Continued.)
Characteristic Genotype 2 or 3 Genotype 2 Genotype 3
Placebo 
for 12 Wk
(N = 85)†
Sofosbuvir 
plus Ribavirin 
for 12 Wk 
(N = 73)
Sofosbuvir 
plus Ribavirin  
for 12 Wk 
(N = 11)
Sofosbuvir 
plus Ribavirin 
for 24 Wk 
(N = 250)
Previous interferon-based treatment — no. (%)
No previous treatment 35 (41) 32 (44) 2 (18) 105 (42)
Eligible 30 (35) 27 (37) 2 (18) 94 (38)
Ineligible‖ 5 (6) 5 (7) 0 11 (4)
Previous treatment 50 (59) 41 (56) 9 (82) 145 (58)
Discontinued owing to side effects** 0 3 (4) 0 10 (4)
No response†† 18 (21) 10 (14) 4 (36) 41 (16)
Relapse or breakthrough infection‡‡ 32 (38) 28 (38) 5 (45) 94 (38)
* Plus–minus values are means ±SD. There were no significant between-group differences at baseline except as indicated. All P values were 
calculated with the use of the Kruskal–Wallis test for continuous variables and the Cochran–Mantel–Haenszel test for categorical vari-
ables. Percentages may not total 100 because of rounding. ULN denotes upper limit of the normal range.
† The mean duration of treatment in the placebo group before the discontinuation of the study group by the sponsor was 7 weeks.
‡ P<0.001 for the comparison among groups.
§ The body-mass index is the weight in kilograms divided by the square of the height in meters.
¶ Race and ethnic group were self-reported.
‖ Ineligibility for interferon treatment was determined by the site investigator on the basis of whether the patients had contraindications to 
interferon therapy.
** Patients were considered to have unacceptable side effects with interferon if they completed 12 weeks or less of treatment (ending ≥3 months 
before screening) with interferon and discontinued treatment because of the development or substantial worsening of at least one of the 
following conditions: local or systemic adverse reaction, psychiatric disease necessitating hospitalization, schizophrenia, bipolar disorder, 
depression, schizoaffective disorder, suicidal ideation or attempt, substantial cognitive impairment, neuropathy, disabling flulike symp-
toms, gastrointestinal toxic effects (nausea, vomiting, or diarrhea), thrombocytopenia (platelet count, <25,000 per cubic millimeter), neu-
tropenia (absolute neutrophil count, <500 per cubic millimeter), colitis, nonalcoholic pancreatitis, ophthalmologic disorders, or various 
autoimmune disorders.
†† Patients were considered to have no response if they did not have undetectable HCV RNA levels at any time during previous treatment.
‡‡ Breakthrough infection was defined as a finding of undetectable HCV RNA levels during treatment but detectable HCV RNA levels before 
the end of treatment. Relapse was defined as a finding of undetectable HCV RNA levels during treatment but detectable HCV RNA levels 
within 4 weeks after the discontinuation of treatment.
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ical significance of these mutations that develop 
during treatment is not known.
Adverse Events
Premature discontinuation of study treatment 
because of adverse events was uncommon in all 
the study groups. One patient in the placebo 
group discontinued therapy because of elevated 
alanine aminotransferase and aspartate amino-
transferase levels, one patient with HCV geno-
type 3 infection receiving 12 weeks of treatment 
discontinued because of malaise and headache, 
and one patient with HCV genotype 3 receiving 
24 weeks of treatment discontinued after at-
tempting suicide. The most common adverse 
events are shown in Table 3. Most adverse events 
occurred with similar frequency in the 12-week 
and 24-week treatment groups. Diarrhea and ir-
ritability were observed more frequently in the 
24-week group than in the 12-week group. No 
single grade 3 or 4 adverse event occurred in 
more than 1% of patients receiving sofosbuvir 
for 12 or 24 weeks. (A complete list of serious 
adverse events is provided in Table S6 in the Sup-
plementary Appendix.)
Among patients receiving 12 weeks of treat-
ment with sofosbuvir–ribavirin, grade 3 labora-
tory abnormalities were reported in 19% of the 
patients and grade 4 abnormalities in 1%; among 
those receiving 24 weeks of therapy, such abnor-
malities were reported in 17% and 1% of the 
patients, respectively. Reductions in hemoglobin 
levels were observed, a finding that was consis-
tent with the expected hemolytic anemia associ-
Table 2. Response during and after Treatment.*
Response Genotype 2 Genotype 3
Sofosbuvir plus 
Ribavirin for 12 Wk 
(N = 73)
Sofosbuvir plus 
Ribavirin for 12 Wk 
(N = 11)
Sofosbuvir plus 
Ribavirin for 24 Wk
(N = 250)
HCV RNA <25 IU/ml during treatment period
At 2 wk
No. of patients 57 6 214
Percent (95% CI) 78 (67–87) 55 (23–83) 86 (81–90)
At 4 wk
No. of patients 73 11 247
Percent (95% CI) 100 (95–100) 100 (72–100) 99 (96–99)
HCV RNA <25 IU/ml after end of treatment
At 4 wk
No. of patients 68 5 218
Percent (95% CI) 93 (85–98) 45 (17–77) 87 (82–91)
At 12 wk
No. of patients 68 3 213
Percent (95% CI) 93 (85–98) 27 (6–61) 85 (80–89)
Virologic failure — no. (%)
During treatment 0 0 1 (<1)†
Relapse
In patients who completed treatment 5 (7) 5 (45) 33 (13)‡
In patients who did not complete treatment 0 1 (9) 1 (<1)
Lost to follow-up 0 2 (18) 2 (1)
* Data are not listed for the placebo group, in which no patients had an HCV RNA level of less than 25 IU per milliliter 
(the lower limit of quantification) at any time point.
† Pharmacokinetic analysis suggested that this patient was nonadherent to the dosing regimen.
‡ Two additional patients had a relapse after post-treatment week 12.
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ated with ribavirin treatment: 6% of patients in 
both the 12-week and 24-week groups had hemo-
globin levels of less than 10 g per deciliter, and 
one patient in each group had a hemoglobin 
level of less than 8.5 g per deciliter. Reductions in 
the dose of ribavirin were performed according 
to the prescribing information and did not ad-
versely influence the treatment outcome (Table S2 
in the Supplementary Appendix). The mean reduc-
tion in hemoglobin level at the end of treatment 
was 2.3 g per deciliter in the 12-week group 
and 2.1 g per deciliter in the 24-week group. 
Transient increases in total serum bilirubin 
were observed to have a temporal association 
with reductions in hemoglobin associated with 
hemolysis.
Discussion
This descriptive study of the oral regimen of so-
fosbuvir in combination with ribavirin, which was 
conducted at nearly 80 sites in Europe, confirmed 
findings from previous studies of sofosbuvir in 
similar populations in North America.13,14 We 
found high rates of sustained virologic response 
among patients with HCV genotype 2 infection 
and among those with genotype 3 infection, with 
a longer treatment duration providing benefit in 
the latter group.
Among patients with HCV genotype 2 infec-
tion, high rates of response and low rates of re-
lapse were observed in all subgroups, indicating 
the efficacy of 12 weeks of treatment in patients 
with this genotype. For patients infected with 
HCV genotype 3, extending sofosbuvir–ribavirin 
treatment to 24 weeks resulted in substantially 
higher rates of response and lower rates of re-
lapse than previously reported with the same 
regimen for 12 weeks and 16 weeks, regardless 
of the status with respect to previous therapy 
and the presence or absence of cirrhosis.12 Ex-
tending the duration of treatment from 12 weeks 
Overall
Age
<50 yr
≥50 yr
Sex
Male
Female
Cirrhosis
No
Yes
HCV RNA level
<6×log10 IU/ml
≥6×log10 IU/ml
Baseline body-mass index
<30
≥30
IL28B genotype
CC
Non-CC
Previous interferon treatment
Yes
No
Rate of Response (%)
Genotype 2, Sofosbuvir
plus Ribavirin for 12 Wk
Genotype 3, Sofosbuvir
plus Ribavirin for 24 Wk
Subgroup
60 8040 70 9050 60 80 100100 40 70 9050
Figure 1. Subgroup Analyses of Sustained Virologic Response.
Shown are rates of sustained virologic response among 73 patients infected with hepatitis C virus (HCV) genotype 2 
and 250 patients infected with HCV genotype 3. The position of the squares indicates the rate of virologic response 
12 weeks after the end of treatment. The horizontal lines indicate 95% confidence intervals. The vertical lines and 
the diamonds represent the overall rates of sustained virologic response. Exact values for these and other subgroup 
results are provided in Table S1 in the Supplementary Appendix.
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to 24 weeks was not associated with increases in 
the severity or frequency of adverse events, nor in 
the rate of treatment discontinuation, which was 
approximately 1% in both the 12-week and 24-
week groups. In addition, the absence of viro-
logic breakthrough during treatment and the 
absence of resistance-associated variants in pa-
tients who had a virologic relapse confirm that 
the sofosbuvir–ribavirin regimen has a high bar-
rier to resistance.
These findings provide further confirmation 
of important differences in response to treatment 
between HCV genotype 2 and genotype 3 and 
the need for a longer treatment duration with 
sofosbuvir–ribavirin in patients with HCV geno-
type 3 infection. The biologic bases and the host 
or viral factors that account for the differences 
in treatment responsiveness between the two geno-
types are not well understood. Between-genotype 
differences in response were not evident during 
Table 3. Adverse Events, Discontinuations, and Hematologic Abnormalities.*
Event
Placebo  
(N = 85)
Sofosbuvir plus 
Ribavirin for 12 Wk, 
Genotype 2 or 3  
(N = 84)
Sofosbuvir plus 
Ribavirin for 24 Wk, 
Genotype 3  
(N = 250)
number of patients (percent)
Any adverse event 60 (71) 72 (86) 229 (92)
Discontinuation of treatment owing to adverse event 1 (1) 1 (1) 1 (<1)
Serious adverse event† 2 (2) 0 10 (4)
Common adverse event‡
Headache 23 (27) 24 (29) 74 (30)
Fatigue 16 (19) 19 (23) 75 (30)
Pruritus 8 (9) 20 (24) 67 (27)
Asthenia 4 (5) 21 (25) 53 (21)
Nausea 9 (11) 26 (31) 33 (13)
Insomnia 2 (2) 9 (11) 41 (16)
Nasopharyngitis 9 (11) 4 (5) 36 (14)
Dry skin 5 (6) 8 (10) 31 (12)
Dyspnea 1 (1) 12 (14) 27 (11)
Cough 4 (5) 8 (10) 27 (11)
Diarrhea 4 (5) 4 (5) 30 (12)
Arthralgia 6 (7) 3 (4) 25 (10)
Irritability 3 (4) 4 (5) 26 (10)
Hematologic event
Decreased hemoglobin
<10 g/dl NA 5 (6) 15 (6)
<8.5 g/dl NA 1 (1) 1 (<1)
Lymphocyte count 350 to <500/mm3 0 1 (1) 5 (2)
Neutrophil count 500 to <750/mm3 1 (1) 1 (1) 0
Platelet count 25,000 to <50,000/mm3 0 0 3 (1)
White-cell count 1000 to 1500/mm3 1 (1) 0 0
* The mean (±SD) durations of treatment were 7.0±3.0 weeks in the placebo group, 12.0±1.2 weeks in the group as-
signed to receive sofosbuvir plus ribavirin for 12 weeks, and 24.0±1.0 weeks in the group assigned to receive sofosbuvir 
plus ribavirin for 24 weeks. NA denotes not available.
† A complete list of serious adverse events is provided in Table S6 in the Supplementary Appendix.
‡ Common adverse events are those that occurred in at least 10% of patients in any study group.
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treatment, since the kinetics of the viral decline 
during the first weeks of treatment were nearly 
identical in patients with genotype 2 infection 
and those with genotype 3 infection. However, 
in a multivariate regression analysis of results, 
we identified four possible predictors of a sus-
tained virologic response among patients with 
genotype 3 infection: female sex, absence of cir-
rhosis, younger age, and a low viral load at base-
line. These four factors have also been regarded 
as predictors of a response to interferon-based 
treatment.15,16 It should be noted that the results 
of this multivariate analysis cannot be regarded 
as definitive without validation in another cohort.
Previously treated patients with HCV geno-
type 3 infection and cirrhosis had the lowest rate 
of sustained virologic response (62%, in 29 of 
47 patients). The cause or causes for this finding 
are not known. Small differences among sub-
groups in the rate of viral decline during the 
first weeks of treatment were no longer evident 
by week 4 (Table S3 in the Supplementary Ap-
pendix). 
Our study has several limitations. First, the 
original design of this study specified 12 weeks, 
rather than 24 weeks, of treatment for patients 
with genotype 3 infection and included com-
parisons with patients in the placebo group. The 
revised design resulted in a descriptive study, 
without any hypothesis testing or formal statis-
tical comparisons. Second, given that few liver-
biopsy specimens were available for the study 
population, questions regarding the extent of 
liver disease, including steatosis and its association 
with relapse among patients with genotype 3 
infection, cannot be adequately addressed. Third, 
although response rates with 12 weeks of treat-
ment were high among patients with HCV geno-
type 2 infection who had characteristics associated 
with a lower response, the small numbers preclude 
definitive conclusions regarding the possible ben-
efits of a longer duration of therapy or the addition 
of peginterferon in harder-to-treat patients.
In conclusion, the oral sofosbuvir–ribavirin 
regimen resulted in high rates of sustained viro-
logic response both in patients with HCV geno-
type 2 infection and in those with genotype 3 
infection. This treatment offers an alternative to 
a peginterferon-based regimen and may make 
possible treatment of a substantial number of 
patients with HCV infection who are ineligible 
to receive interferon because of absolute or rela-
tive contraindications.
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